Chronic kidney disease at one year after liver transplantation: Role of changes in immunosuppression over three decades

Table 7 Patients treated with tacrolimus classified according to whether they received induction treatment with basiliximab, n (%)/median (25^th-75^th percentiles)/mean ± SD

Variables	Without basiliximab, (n = 135)	With basiliximab, (n = 240)	P value
Pre-transplant variables
Age in years	52.7 (44.3-59.0)	56.2 (50.0-61.1)	< 0.001
Female sex	36 (26.5)	60 (25.2)	0.884
HTN	17 (12.5)	51 (21.4)	0.044
DM	20 (14.7)	60 (25.2)	0.024
BMI (kg/m2)	25.0 ± 3.8	26.4 ± 3.9	0.003
LT indication			0.001
Cirrhosis without tumor	97 (71.3)	123 (51.7)
HCC	33 (24.3)	97 (40.8)
AFH	2 (1.5)	6 (2.5)
Other	1 (0.7)	11 (4.6)
Other tumors	3 (2.2)	1 (0.4)
Child-Pugh			0.004
A	16 (11.8)	59 (24.8)
B	69 (50.7)	89 (37.4)
C	43 (31.6)	72 (30.3)
No cirrhosis	8 (5.9)	18 (7.6)
Pre-transplant RD	24 (17.6)	41 (17.2)	0.918
Post-transplant variables
Immunosuppression			< 0.001
Steroids	118 (86.8)	59 (24.8)
MPA	34 (25)	202 (84.8)
Tac levels (ng/mL)
At 1 month	9.55 (7.0-13.6)	8.1 (5.9-10.1)	< 0.001
At 6 months	10 (7.7-12.7)	7 (5.6-9.3)	< 0.001
At 1 year	8.2 (6.0-10.8)	7 (5.1-8.5)	< 0.001
HTN at 6 months	32 (23.7)	76 (33.2)	0.073
DM at 6 months	45 (33.3)	81 (34.3)	0.937
Renal dysfunction
At 1 month	62 (45.6)	61 (25.7)	< 0.001
At 6 months	57 (42.2)	78 (33.1)	0.078
CKD at 1 year	61 (44.9)	85 (35.71)	0.103

AFH: Acute fulminant hepatitis; BMI: Body mass index; CsA: Cyclosporine A; DM: Diabetes mellitus; HCC: Hepatocellular carcinoma; HTN: Arterial hypertension; LT: Liver transplant; MPA: Mycophenolic acid; RD: Renal dysfunction; Tac: Tacrolimus.